Literature DB >> 20711763

Nonclinical dose formulation analysis method validation and sample analysis.

Monica Lee Whitmire1, Peter Bryan, Teresa R Henry, John Holbrook, Paul Lehmann, Thomas Mollitor, Susan Ohorodnik, David Reed, Holly D Wietgrefe.   

Abstract

Nonclinical dose formulation analysis methods are used to confirm test article concentration and homogeneity in formulations and determine formulation stability in support of regulated nonclinical studies. There is currently no regulatory guidance for nonclinical dose formulation analysis method validation or sample analysis. Regulatory guidance for the validation of analytical procedures has been developed for drug product/formulation testing; however, verification of the formulation concentrations falls under the framework of GLP regulations (not GMP). The only current related regulatory guidance is the bioanalytical guidance for method validation. The fundamental parameters for bioanalysis and formulation analysis validations that overlap include: recovery, accuracy, precision, specificity, selectivity, carryover, sensitivity, and stability. Divergence in bioanalytical and drug product validations typically center around the acceptance criteria used. As the dose formulation samples are not true "unknowns", the concept of quality control samples that cover the entire range of the standard curve serving as the indication for the confidence in the data generated from the "unknown" study samples may not always be necessary. Also, the standard bioanalytical acceptance criteria may not be directly applicable, especially when the determined concentration does not match the target concentration. This paper attempts to reconcile the different practices being performed in the community and to provide recommendations of best practices and proposed acceptance criteria for nonclinical dose formulation method validation and sample analysis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20711763      PMCID: PMC2976985          DOI: 10.1208/s12248-010-9226-9

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  5 in total

1.  Bioanalytical method validation--a revisit with a decade of progress.

Authors:  V P Shah; K K Midha; J W Findlay; H M Hill; J D Hulse; I J McGilveray; G McKay; K J Miller; R N Patnaik; M L Powell; A Tonelli; C T Viswanathan; A Yacobi
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

2.  Nonclinical laboratory studies: good laboratory practice regulations.

Authors: 
Journal:  Fed Regist       Date:  1978-12-22

3.  International Conference on Harmonisation; guidance on Q6A specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances. Notice.

Authors: 
Journal:  Fed Regist       Date:  2000-12-29

4.  Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays.

Authors:  C T Viswanathan; Surendra Bansal; Brian Booth; Anthony J DeStefano; Mark J Rose; Jeffrey Sailstad; Vinod P Shah; Jerome P Skelly; Patrick G Swann; Russell Weiner
Journal:  Pharm Res       Date:  2007-04-26       Impact factor: 4.200

5.  Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report.

Authors:  V P Shah; K K Midha; S Dighe; I J McGilveray; J P Skelly; A Yacobi; T Layloff; C T Viswanathan; C E Cook; R D McDowall
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Oct-Dec       Impact factor: 2.441

  5 in total
  5 in total

1.  A HPLC method for the quantitative determination of N-(2-hydroxy-5-nitrophenylcarbamothioyl)-3,5-dimethylbenzamide in biological samples.

Authors:  Igor Skidan; Jacob Grunwald; Ritesh Thekkedath; Alexei Degterev; Vladimir Torchilin
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-04-06       Impact factor: 3.205

2.  Nonclinical dose formulation: out of specification investigations.

Authors:  Troy Appleton; Peter Bryan; Denise Contos; Teresa R Henry; Paul Lehmann; Susan Ohorodnik; Dave Reed; Chantal Robichaud; John Schetter; Natalie South; John Weissmann; Monica Lee Whitmire
Journal:  AAPS J       Date:  2012-05-08       Impact factor: 4.009

Review 3.  Best Practices in Stability Indicating Method Development and Validation for Non-clinical Dose Formulations.

Authors:  Teresa R Henry; Lara D Penn; Jason R Conerty; Francesca E Wright; Gregory Gorman; Brian W Pack
Journal:  AAPS J       Date:  2016-09-06       Impact factor: 4.009

4.  The need to compare: assessing the level of agreement of three high-throughput assays against Plasmodium falciparum mature gametocytes.

Authors:  Leonardo Lucantoni; Sasdekumar Loganathan; Vicky M Avery
Journal:  Sci Rep       Date:  2017-04-05       Impact factor: 4.379

5.  Safety of Algal Oil Containing EPA and DHA in cats during gestation, lactation and growth.

Authors:  Anna Vuorinen; Eileen Bailey-Hall; Alexios Karagiannis; Shiguang Yu; Franz Roos; Erin Sylvester; Jon Wilson; Irina Dahms
Journal:  J Anim Physiol Anim Nutr (Berl)       Date:  2020-02-18       Impact factor: 2.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.